These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 1678420)

  • 1. Somatostatin cerebrospinal fluid levels in dementia.
    Molins A; Catalán R; Sahuquillo J; Castellanos JM; Codina A; Galard R
    J Neurol; 1991 Jun; 238(3):168-70. PubMed ID: 1678420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerebrospinal fluid somatostatin in delirium.
    Koponen H; Stenbäck U; Mattila E; Reinikainen K; Soininen H; Riekkinen PJ
    Psychol Med; 1989 Aug; 19(3):605-9. PubMed ID: 2572025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuropeptides in cerebrospinal fluid in normal-pressure hydrocephalus and dementia.
    Wikkelsö C; Ekman R; Westergren I; Johansson B
    Eur Neurol; 1991; 31(2):88-93. PubMed ID: 1675171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CSF somatostatin-like immunoreactivity in dementia.
    Beal MF; Growdon JH; Mazurek MF; Martin JB
    Neurology; 1986 Feb; 36(2):294-7. PubMed ID: 2868429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cerebrospinal fluid somatostatin and neuropeptide Y. Concentrations in aging and in dementia of the Alzheimer type with and without extrapyramidal signs.
    Atack JR; Beal MF; May C; Kaye JA; Mazurek MF; Kay AD; Rapoport SI
    Arch Neurol; 1988 Mar; 45(3):269-74. PubMed ID: 2893600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Somatostatin and neuropeptide Y in cerebrospinal fluid: correlations with severity of disease and clinical signs in Alzheimer's disease and frontotemporal dementia.
    Minthon L; Edvinsson L; Gustafson L
    Dement Geriatr Cogn Disord; 1997; 8(4):232-9. PubMed ID: 9213068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Processing of neuropeptide Y, galanin, and somatostatin in the cerebrospinal fluid of patients with Alzheimer's disease and frontotemporal dementia.
    Nilsson CL; Brinkmalm A; Minthon L; Blennow K; Ekman R
    Peptides; 2001 Dec; 22(12):2105-12. PubMed ID: 11786197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebrospinal fluid neuropeptides in mood disorder and dementia.
    Banki CM; Karmacsi L; Bissette G; Nemeroff CB
    J Affect Disord; 1992 May; 25(1):39-45. PubMed ID: 1352520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of the course of senile dementia of the Alzheimer type using cerebrospinal fluid levels of acetylcholinesterase and somatostatin.
    Urakami K; Adachi Y; Awaki E; Takahashi K
    Acta Neurol Scand; 1989 Sep; 80(3):232-7. PubMed ID: 2572139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CSF somatostatin in Alzheimer's disease.
    Serby M; Richardson SB; Twente S; Siekierski J; Corwin J; Rotrosen J
    Neurobiol Aging; 1984; 5(3):187-9. PubMed ID: 6151123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular size distribution of somatostatin-like immunoreactivity in the cerebrospinal fluid of patients with degenerative brain disease.
    Rissler K; Cramer H; Schaudt D; Strubel D; Gattaz WF
    Neurosci Res; 1986 Feb; 3(3):213-25. PubMed ID: 2871533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meningeal derived cerebrospinal fluid proteins in different forms of dementia: is a meningopathy involved in normal pressure hydrocephalus?
    Brettschneider J; Riepe MW; Petereit HF; Ludolph AC; Tumani H
    J Neurol Neurosurg Psychiatry; 2004 Nov; 75(11):1614-6. PubMed ID: 15489398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced lumbar CSF somatostatin levels in Alzheimer's disease.
    Wood PL; Etienne P; Lal S; Gauthier S; Cajal S; Nair NP
    Life Sci; 1982 Nov; 31(19):2073-9. PubMed ID: 6184590
    [No Abstract]   [Full Text] [Related]  

  • 14. Somatostatin-like immunoreactivity and substance-P-like immunoreactivity in the CSF of patients with senile dementia of Alzheimer type, multi-infarct syndrome and communicating hydrocephalus.
    Cramer H; Schaudt D; Rissler K; Strubel D; Warter JM; Kuntzmann F
    J Neurol; 1985; 232(6):346-51. PubMed ID: 2416886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dementia--and adenylate kinase activity in cerebrospinal fluid.
    Ahlberg J; Blomstrand C; Ronquist G; Wikkelsö C
    Acta Neurol Scand; 1985 Nov; 72(5):525-7. PubMed ID: 4082920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peptide histidine methionine in cerebrospinal fluid of patients with senile dementia of the Alzheimer type.
    Yasuda M; Minamitani N; Maeda K
    Jpn J Psychiatry Neurol; 1993 Mar; 47(1):85-90. PubMed ID: 8105129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GH response to GH-releasing hormone (GHRH) in Alzheimer and vascular dementia. Relation with somatostatin cerebrospinal levels.
    Gómez IM; Aguilar M; Navarro MA; Ortolà J; Soler J
    Ann Endocrinol (Paris); 1996; 57(2):107-10. PubMed ID: 8881289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amino acid concentration in dementia of the Alzheimer type and multi-infarct dementia.
    Mochizuki Y; Oishi M; Hara M; Takasu T
    Ann Clin Lab Sci; 1996; 26(3):275-8. PubMed ID: 8726221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patients with Alzheimer's disease show an increased content of 15 Kdalton somatostatin precursor and a lowered level of tetradecapeptide in their cerebrospinal fluid.
    Gomez S; Puymirat J; Valade P; Davous P; Rondot P; Cohen P
    Life Sci; 1986 Aug; 39(7):623-7. PubMed ID: 2874467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship of interleukin-1 beta and beta 2-microglobulin with neuropeptides in cerebrospinal fluid of patients with dementia of the Alzheimer type.
    Martinez M; Frank A; Hernanz A
    J Neuroimmunol; 1993; 48(2):235-40. PubMed ID: 7693756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.